A population‐based study of prognosis in advanced stage follicular lymphoma managed by watch and wait

Tarec Christoffer El‐Galaly(Aalborg University Hospital), Martin Hutchings(University of Copenhagen), Anne Ortved Gang(University of Copenhagen), Robert Schou Pedersen, Syed Azhar Ahmad(Copenhagen University Hospital), Peter de Nully Brown(Copenhagen University Hospital), Karen Juul Mylam(Odense University Hospital), Hans Erik Johnsen(Herlev Hospital), Maja Bech Juul(Vejle Sygehus), Martin Bøgsted(Chr. Hansen (Denmark)), Anders Ellern Bilgrau(Chr. Hansen (Denmark)), Olav J. Bergmann(Hospital South West Jutland), Hans Bentzen(Aarhus University Hospital), Lars Møller Pedersen(Hospital South West Jutland), Berit Jamie Nielsen(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital)
British Journal of Haematology
February 23, 2015
10.1111/bjh.13316
Cited by 38

Related Papers

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
|Journal of Clinical Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396